Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Aug 2, 2017

Dr. Dror Harats, Founder and CEO of VBL Therapeutics, talks about the limitations of current treatments for recurrent glioblastoma multiforme (rGBM), the most common and deadliest form of brain cancer in adults and the challenges in developing new treatments to combat this devastating disease. The good news is that their lead candidate, a biologic agent called VB-111, is in late-stage clinical development for rGBM and showing great promise. He discusses the unique mechanism of VB-111 that he hopes could hold the key not only to treating rGBM, but many types of cancer.

@VBL Therapeutic

#GBM.  #Glioblastoma. 

#BrainTumor   #BrainCancer.  #Cancer

VBL Therapeutics VBLRX.com